Managers / Q4 2025 · view latest →
Bellevue Group AG
CIK 0001674546 · THEATERSTRASSE 12, ZURICH, CH-8001 · 41 44 267 67 77
Reported Value
$5.3B
Q4 2025
Positions
213
Filings on Record
30
2019–present window
Filed
Feb 17, 2026
original filing
Summary
Bellevue Group Ag reported $5.3B in U.S.-listed holdings across 213 positions for Q4 2025.
Its largest position, RVMD, represents 7.5% of the portfolio.
Compared with Q3 2025, the fund opened 37 new positions and exited 9.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
Composition data arrives with ticker enrichment.
Quarter-over-Quarter Changes full breakdown →
Holdings — Q4 2025
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $4.2B | 167 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $5.3B | 213 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $4.8B | 186 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $4.5B | 175 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $4.5B | 177 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $5.2B | 193 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $6.2B | 196 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $6.2B | 204 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $6.6B | 208 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $6.5B | 202 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $6.2B | 196 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $7.0B | 198 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $6.9B | 202 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $7.53T | 215 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $7.0B | 217 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $7.1B | 214 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $8.6B | 220 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $9.7B | 235 | Feb 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $9.9B | 265 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $10.2B | 262 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $9.5B | 260 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $8.7B | 266 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $7.2B | 261 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $7.1B | 235 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $5.2B | 239 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $6.3B | 239 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $5.4B | 236 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $5.9B | 219 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.8B | 138 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $1.5B | 138 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 3 additional managers.
- BB BIOTECH AG028-06964
- Bellevue Asset Management AG028-16892
- Bellevue Asset Management (UK) Ltd.028-20408
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.